Ultimovacs Feed

	Tid*
2025-02-13	07:30	Bokslutskommuniké 2024
2025-01-09	N/A	Extra Bolagsstämma 2025
2024-11-06	-	Kvartalsrapport 2024-Q3
2024-08-21	-	Kvartalsrapport 2024-Q2
2024-05-07	-	Kvartalsrapport 2024-Q1
2024-04-25	-	X-dag ordinarie utdelning ULTI 0.00 NOK
2024-04-24	-	Årsstämma
2024-02-14	-	Bokslutskommuniké 2023
2023-11-08	-	Kvartalsrapport 2023-Q3
2023-08-22	-	Kvartalsrapport 2023-Q2
2023-05-10	-	Kvartalsrapport 2023-Q1
2023-04-21	-	X-dag ordinarie utdelning ULTI 0.00 NOK
2023-04-20	-	Årsstämma
2023-02-16	-	Bokslutskommuniké 2022
2022-11-10	-	Kvartalsrapport 2022-Q3
2022-08-19	-	Kvartalsrapport 2022-Q2
2022-05-12	-	Kvartalsrapport 2022-Q1
2022-04-21	-	X-dag ordinarie utdelning ULTI 0.00 NOK
2022-04-20	-	Årsstämma
2022-02-17	-	Bokslutskommuniké 2021
2021-11-11	-	Kvartalsrapport 2021-Q3
2021-08-20	-	Kvartalsrapport 2021-Q2
2021-05-11	-	Kvartalsrapport 2021-Q1
2021-04-22	-	X-dag ordinarie utdelning ULTI 0.00 NOK
2021-04-21	-	Årsstämma
2021-02-17	-	Bokslutskommuniké 2020
2020-11-12	-	Kvartalsrapport 2020-Q3
2020-11-11	-	Extra Bolagsstämma 2020
2020-08-21	-	Kvartalsrapport 2020-Q2
2020-05-14	-	Kvartalsrapport 2020-Q1
2020-04-16	-	X-dag ordinarie utdelning ULTI 0.00 NOK
2020-04-15	-	Årsstämma
2020-02-14	-	Bokslutskommuniké 2019
2019-11-14	-	Kvartalsrapport 2019-Q3
2019-08-21	-	Kvartalsrapport 2019-Q2

Land	Norge
Lista	OB Match
Sektor	Hälsovård
Industri	Bioteknik

2024-12-19 09:37:54 Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION 2,65 NOK | -3,81% | 2,20 MNOK

2024-12-19 07:00:00 Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 2,65 NOK | -3,81% | 2,20 MNOK

2024-12-18 08:00:00 ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY 2,75 NOK | +14,79% | 11,7 MNOK

2024-12-18 08:00:00 ULTI - EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY 2,75 NOK | +14,79% | 11,7 MNOK

2024-12-17 19:39:15 Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA 2,75 NOK | +14,79% | 11,7 MNOK

2024-12-17 19:25:09 Ultimovacs ASA – Mandatory notification of trade 2,75 NOK | +14,79% | 11,7 MNOK

2024-12-17 17:53:50 ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT 2,75 NOK | +14,79% | 11,7 MNOK

2024-11-06 07:00:00 Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update 1,85 NOK | +6,94% | 1,07 MNOK

2024-10-31 07:00:00 Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation 1,70 NOK | -3,19% | 0,22 MNOK

2024-10-25 17:00:00 Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

2024-10-25 17:00:00 ULTI: Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

2024-09-11 17:00:00 Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer 1,91 NOK | -22,04% | 4,83 MNOK

2024-09-09 00:10:00 Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024

2024-08-21 07:00:00 Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update 3,03 NOK | -11,40% | 1,07 MNOK

2024-08-15 07:00:00 Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation 3,50 NOK | 0,00% | 1,16 MNOK

2024-08-07 13:59:52 Ultimovacs Announces Notice of Resignation from Deputy Board Member 3,30 NOK | 0,00% | 3,80 MNOK

2024-08-05 19:12:00 Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer 3,30 NOK | -55,70% | 18,4 MNOK

2024-08-01 17:20:00 Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 8,10 NOK | -6,25% | 2,33 MNOK

2024-08-01 17:20:00 ULTI: Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 8,10 NOK | -6,25% | 2,33 MNOK

2024-06-24 21:00:00 Ultimovacs ASA announces revised terms of the employee share option program 7,80 NOK | -1,02% | 0,41 MNOK

2024-06-11 07:00:00 Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab 9,17 NOK | +21,94% | 36,0 MNOK

2024-06-01 14:15:00 Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

2024-06-01 14:15:00 ULTI: Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

2024-05-07 07:00:00 Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update 7,29 NOK | -6,18% | 12,2 MNOK

2024-04-30 07:00:00 Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation 6,98 NOK | +0,29% | 2,13 MNOK

2024-04-24 16:15:00 Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 7,58 NOK | -3,56% | 3,80 MNOK

2024-04-24 16:14:55 ULTI: Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting 7,58 NOK | -3,56% | 3,80 MNOK

2024-04-18 14:42:30 Ultimovacs ASA – Annual General Meeting held on April 18, 2024 8,36 NOK | -4,46% | 7,50 MNOK

2024-04-16 22:10:00 Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program 8,75 NOK | -13,37% | 26,1 MNOK

2024-04-15 07:00:00 Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting 9,93 NOK | -0,40% | 12,2 MNOK

2024-04-09 20:00:00 Ultimovacs – Invitation to Business Update on April 17, 2024 10,04 NOK | +9,49% | 26,1 MNOK

2024-04-09 20:00:00 Ultimovacs - Invitation to Business Update on April 17, 2024 10,04 NOK | +9,49% | 26,1 MNOK

2024-04-04 07:00:00 Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 11,00 NOK | -6,78% | 69,0 MNOK

2024-03-25 07:00:00 Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 7,90 NOK | +1,28% | 10,7 MNOK

2024-03-22 13:27:23 Ultimovacs ASA: Mandatory notification of trade by primary insider 7,80 NOK | +23,22% | 19,9 MNOK

2024-03-21 07:00:00 Ultimovacs ASA: Annual Report 2023 6,33 NOK | -9,05% | 7,09 MNOK

2024-03-09 11:00:00 Ultimovacs ASA: Mandatory notification of trades by primary insider 7,60 NOK | -5,00%

2024-03-08 23:00:00 Ultimovacs ASA: Mandatory notification of trades by primary insider 7,60 NOK | -5,00%

2024-03-08 08:13:05 Ultimovacs ASA - Mandatory trade notification and disclosure of holding 8,00 NOK | -8,05% | 84,1 MNOK

2024-03-07 23:00:00 Ultimovacs ASA: Mandatory notification of trade by primary insiders 8,00 NOK | -8,05% | 84,1 MNOK

2024-03-07 16:37:27 Ultimovacs ASA - Disclosure of shareholding 8,00 NOK | -8,05% | 84,1 MNOK

2024-03-07 11:26:09 Ultimovacs ASA - Disclosure of shareholding 8,70 NOK | -92,68% | 227 MNOK

2024-03-07 07:00:00 Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma 8,70 NOK | -92,68% | 227 MNOK

2024-03-02 18:41:22 Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer 117,20 NOK | -13,31%

2024-03-02 18:41:17 ULTI: Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer 117,20 NOK | -13,31%

2024-02-19 07:00:00 Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma 147,00 NOK | +8,73% | 41,3 MNOK

2024-02-14 07:00:00 Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update 137,00 NOK | +1,18% | 11,7 MNOK

2024-02-08 08:00:00 Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation 131,20 NOK | -0,30% | 10,6 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Ultimovacs

Kalender

Beskrivning

Ultimovacs

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden